Skip to content

Gene Biotherapeutics, Inc.

CIK 0000772320

← back to feed
Revenue (TTM)
$19.2K
+83.8% YoY FY Mar 2022
Net Income (TTM)
−$205.78K
−135.7% YoY FY Mar 2022
EPS Diluted (TTM)
$0.10
+1,100.0% YoY FY Mar 2022
Gross Margin
36.7%
FY Mar 2022
Operating Margin
-1,873.6%
FY Mar 2022
Net Margin
-1,071.7%
FY Mar 2022
Free Cash Flow (TTM)
−$2.53M
FY Mar 2022
Cash
$386.03K
FY Mar 2022
Total Debt
—
FY Mar 2022
Shares Outstanding
64.93M sh
FY Mar 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings